Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Simulations Plus Releases ADMET Predictor® (X.3): https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Releases ADMET Predictor® (X.3)


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemical, and consumer goods industries, today announced that it

Hanger to Present at the Baird 2021 Global Healthcare Conference
Hanger to Present at the Baird 2021 Global Healthcare Conference


Hanger, Inc. (NYSE: HNGR), a leading provider of orthotic and prosthetic patient care services and solutions, announced today that members of its management team will participate virtually in

Waters BioAccord System with ACQUITY Premier Brings Greater Simplicity, Accuracy and Reproducibility to Multi-Attribute Monitoring of Biopharmaceuticals
Waters BioAccord System with ACQUITY Premier Brings Greater Simplicity, Accuracy and Reproducibility to Multi-Attribute Monitoring of Biopharmaceuticals


Waters Corporation (NYSE:WAT) today introduced the Waters™ BioAccord™ System with ACQUITY™ Premier, a combination of the Waters BioAccord System and the breakthrough ACQUITY Premier UPLC™ with

Novocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combination for the First-line Treatment of Metastatic Pancreatic Cancer: https://mms.businesswire.com/media/20191120005453/en/721126/5/novocure_main%405x.jpg
Novocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combination for the First-line Treatment of Metastatic Pancreatic Cancer


Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with Roche (SIX: RO. ROG; OTCQX: RHHBY), to develop Tumor Treating Fields (TTFields) together

Non-insured Health Benefits Program Now Covers Dexcom G6 Continuous Glucose Monitoring System for Children and Adolescents on Intensive Insulin Therapy
Non-insured Health Benefits Program Now Covers Dexcom G6 Continuous Glucose Monitoring System for Children and Adolescents on Intensive Insulin Therapy


Dexcom, Inc. (NASDAQ: DXCM), a leader in real-time continuous glucose monitoring (CGM), is pleased to announce the Dexcom G6 CGM System is now covered by the Non-Insured Health Benefits (NIHB)

NanoString to Webcast Presentation from the Baird 2021 Global Healthcare Conference: https://mms.businesswire.com/media/20191104005218/en/753909/5/NSTG-Logo-19-%28002%29.jpg
NanoString to Webcast Presentation from the Baird 2021 Global Healthcare Conference


NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast a

Humana Expands Upon Its Bold Goal Initiative with $25 Million Affordable Housing Investment: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana Expands Upon Its Bold Goal Initiative with $25 Million Affordable Housing Investment


As part of its population health strategy to improve the health of its members and communities, Humana Inc. (NYSE: HUM) today announced a $25 million investment to increase the supply of affordable

FDA Grants Breakthrough Device Designation to the NovoTTF-200T™ System for Advanced Liver Cancer
FDA Grants Breakthrough Device Designation to the NovoTTF-200T™ System for Advanced Liver Cancer


Novocure (NASDAQ: NVCR) today announced the United States Food and Drug Administration (FDA) has granted breakthrough designation to the NovoTTF-200T System, a Tumor Treating Fields (TTFields)

UK’s MHRA Grants Marketing Authorisation for Pfizer’s CIBINQO® (abrocitinib) for Adults and Adolescents With Moderate to Severe Atopic Dermatitishttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
UK’s MHRA Grants Marketing Authorisation for Pfizer’s CIBINQO® (abrocitinib) for Adults and Adolescents With Moderate to Severe Atopic Dermatitis


Pfizer Inc. (NYSE: PFE) today announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted Great Britain marketing authorization for CIBINQO® (abrocitinib), an oral

Curant Health and Humana Launch Pilot Program to Address Medication Adherence and Enhance Patient Care for Members with Complex Health Needs: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Curant Health and Humana Launch Pilot Program to Address Medication Adherence and Enhance Patient Care for Members with Complex Health Needs


Curant Health and Humana Inc. (NYSE: HUM) have teamed up to help achieve better health outcomes for Humana members suffering from Chronic Heart Failure (CHF) and Chronic Obstructive Pulmonary

Simulations Plus to Participate in BofA Securities and Oppenheimer Investor Conferences: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus to Participate in BofA Securities and Oppenheimer Investor Conferences


Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that chief executive officer Shawn

Premier Inc. and 11 Leading Health Systems Invest in Exela Pharma Sciences to Secure and Support U.S.- Based Drug Supply and Manufacturing: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier Inc. and 11 Leading Health Systems Invest in Exela Pharma Sciences to Secure and Support U.S.- Based Drug Supply and Manufacturing


Premier Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, and 11 leading health systems acquired a minority stake in Exela Holdings, Inc., the holding company of

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)


Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that on September 1, 2021, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement

Puma Biotechnology to Present at the H.C. Wainwright 23rd Annual Global Investment Conference: https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology to Present at the H.C. Wainwright 23rd Annual Global Investment Conference


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of

Pfizer Invites Public to Listen to Two Webcasts of Pfizer Discussions at Upcoming Healthcare Conferenceshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Invites Public to Listen to Two Webcasts of Pfizer Discussions at Upcoming Healthcare Conferences


Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to two webcasts of discussions with Pfizer executives at two upcoming healthcare conferences.



Frank D’Amelio, Chief

Charles River Laboratories to Participate in September Investor Conferences: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories to Participate in September Investor Conferences


Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at three upcoming investor conferences, including:




  • Wells Fargo 2021 Healthcare

Savara to Participate in Two Upcoming Investor Healthcare Conferences: https://mms.businesswire.com/media/20200730005071/en/747459/5/SavaraLogo.jpg
Savara to Participate in Two Upcoming Investor Healthcare Conferences


Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the following healthcare

Agilent Announces Thought Leader Award to David R. Liu at the Broad Institute:
Agilent Announces Thought Leader Award to David R. Liu at the Broad Institute


Agilent Technologies Inc. (NYSE: A) today announced Dr. David R. Liu has been selected to receive a prestigious Agilent Thought Leader Award. A prominent researcher in the field of genome editing

Premier Inc. Reduces Board Size and Further Enhances Corporate Governance Profile: https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier Inc. Reduces Board Size and Further Enhances Corporate Governance Profile


Premier, Inc. (NASDAQ: PINC) today announced it has decreased the size of its Board of Directors from 15 to 11, effective August 31, 2021, to further enhance the company’s governance profile. In

Humana Foundation Donates $500,000 to Support Disaster Recovery in the Wake of Hurricane Ida: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana Foundation Donates $500,000 to Support Disaster Recovery in the Wake of Hurricane Ida


The Humana Foundation, philanthropic arm of Humana Inc. (NYSE: HUM) for the past 40 years, is donating $500,000 towards relief and recovery efforts for those impacted by Hurricane Ida in Louisiana

Savara Announces New Employment Inducement Grants Under NASDAQ Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20200730005071/en/747459/5/SavaraLogo.jpg
Savara Announces New Employment Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)


Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.



On September 2

Dexcom Announces Upcoming Virtual Conference Presentations: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Announces Upcoming Virtual Conference Presentations


DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming virtual investor conferences:




  • Jereme Sylvain, Executive Vice President and

Agilent and Visiopharm Expand Collaboration with Worldwide Distribution Agreement: https://unsplash.com/photos/MJX7-BAdkt0
Agilent and Visiopharm Expand Collaboration with Worldwide Distribution Agreement


Agilent Technologies Inc. (NYSE: A) today announced the signing of a worldwide distribution agreement with Visiopharm, enabling Agilent to co-market Visiopharm’s portfolio of CE-IVD marked

Deciphera Pharmaceuticals, Inc. to Present at the 19th Annual Morgan Stanley Global Healthcare Conference
Deciphera Pharmaceuticals, Inc. to Present at the 19th Annual Morgan Stanley Global Healthcare Conference


Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the 19th Annual Morgan Stanley

Pfizer Announces Start of Phase 3 Clinical Trial in Adults for Its Investigational Vaccine Against Respiratory Syncytial Virus (RSV)http://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Announces Start of Phase 3 Clinical Trial in Adults for Its Investigational Vaccine Against Respiratory Syncytial Virus (RSV)


Pfizer Inc. (NYSE:PFE) today announced the initiation of RENOIR (RSV vaccine Efficacy study iN Older adults Immunized against RSV disease), a Phase 3 clinical trial evaluating the efficacy